Peer-influenced content. Sources you trust. No registration required. This is HCN.
Journal of the National Cancer Institute (JNCI)
Daily low-dose endoxifen reduced mammographic breast density versus placebo in premenopausal women, with fewer tolerability concerns at 1 mg. Whether this surrogate response translates into lower breast cancer incidence remains unknown.
Medical Oncology August 31st 2026
Cancer Therapy Advisor
A phase 1 study of mKRAS-VAX in 20 patients at high risk for PDAC showed KRAS-specific T-cell responses in most participants. No high-grade adverse events occurred, but clinical prevention data remain early.
Medical Oncology August 18th 2026
Healthline
Low-dose (Z)-endoxifen significantly reduced mammographic breast density in premenopausal women while producing fewer treatment-related symptoms than expected with standard tamoxifen exposure. The phase II findings suggest a potential new prevention strategy, but effects on actual breast cancer incidence remain unknown.
Medical Oncology August 13th 2026
Medical News Today (MNT)
GLP-1 receptor agonist use was associated with a 41% lower overall risk of obesity-related cancers in a retrospective cohort of more than 229,000 non-diabetic patients with obesity, with the largest risk reductions observed in endometrial, pancreatic, colorectal, and multiple myeloma.
Hematology/Oncology June 22nd 2026
Health
Many adults remain unaware that processed meat is linked to colorectal cancer, highlighting the need for clearer communication around diet, risk magnitude, and screening.
Ambulatory Care Nursing April 16th 2026
MDLinx
“We show that following the guidelines as a whole benefits public health — a sustainable Nordic diet benefits public health and the climate.” — Christina Dahm, Associate Professor, Aarhus University
Family Medicine/General Practice March 16th 2026